Moderna announced Tuesday afternoon that its vaccine trial had produced a “robust” immune response in all 45 of its participants.

Moderna stock was up over 14% after-hours, and is up 297% year-to-date.

The company received criticism in May for releasing incomplete results from its Phase 1 trial, and for numerous insiders selling shares.

Moderna CEO Stéphane Bancel has made 46 transactions in Moderna stock this year; all of them were sales of stock. Bancel has sold 571,730 shares this year for a total of $23,814,499.

Bancel still directly owns over 6.7 million shares, according to his latest Form 4.